Nalaganje...

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer

PURPOSE: Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110α, has shown synergistic anti-tumor activity with endocrine therapy against ER+/PIK3CA mutated breast cancer cells. This phase Ib study evaluated alpelisib plus letrozole’s safety, tolerability and preliminary a...

Popoln opis

Shranjeno v:

Bibliografske podrobnosti
izdano v:	Clin Cancer Res
Main Authors:	Mayer, Ingrid A., Abramson, Vandana G., Formisano, Luigi, Balko, Justin M., Estrada, Mónica V., Sanders, Melinda E., Juric, Dejan, Solit, David, Berger, Michael F., Won, Helen H., Li, Yisheng, Cantley, Lewis C., Winer, Eric, Arteaga, Carlos L.
Format:	Artigo
Jezik:	Inglês
Izdano:	2016
Teme:	Article
Online dostop:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5085926/ https://ncbi.nlm.nih.gov/pubmed/27126994 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0134
Oznake:	Označite Brez oznak, prvi označite!

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer

Podobne knjige/članki